Regenerative Approaches in Type 1 Diabetes: β-cell Replacement and Emerging Therapeutics.

Type 1 diabetes (T1D) is a selective autoimmune loss of insulin-secreting pancreatic β-cells and lifelong replacement with exogenous insulin. The disease remains incurable despite extensive research. New therapies, such as stem cell replacement, have been developed as the leading β-cell replacement modality. Pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have been established as insulin-secreting cells, a theoretically unlimited reservoir for transplantation. Defective β-cell function, immune rejection, and ethical issues still exist. New immunosuppressive measures such as costimulation blockade therapy or regulatory T cell (Treg)-based therapy have been proposed to optimize graft survival with fewer side effects. Bioengineered islet grafting, xenograft transplantations, and gene editing tools are also analyzed in order to improve the effectiveness of β-cell replacement. Therapeutic advances in target immunomodulation and islet encapsulation are also enhancing survival and functionality of transplanted cells. This article provides a pharmaceutical review of emerging β-cell replacement therapies including stem cell-derived therapy, immunotherapy, and innovative biotechnologybased solutions. Breaking through current limitations of these therapies is crucial to achieving long-term insulin independence for T1D patients. Refining differentiation protocols, improving immune evasion strategies, and merging paradigms of personalized medicine are essential to achieving maximal therapeutic benefit in future studies.